Clinical trial for Schizophrenia and Predominant Negative Symptoms
Official title Accelerated Neuromodulation Therapy for Negative Symptoms of Schizophrenia
ClinicalTrials.gov ID: NCT07428460
What this study is testing
- What it's testing
- The study wants to find out if this quick treatment is safe and can reduce negative symptoms like low motivation and difficulty with social interaction.
- Who it's for
- It is looking for adults with schizophrenia who mainly have negative symptoms.
- What's involved
- Participants will have interviews, questionnaires, a brain scan, and receive either real or sham neuromodulation therapy for five days, then follow‑up visits.
- Time commitment
- The study lasts about a week of daily treatment plus several follow‑up visits over the next few months.
You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Confirmed diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder
- Duration of illness ≥ 6 months
- Clinically significant negative symptoms
- Must have been on a stable pharmacological treatment for at least 4 weeks before entering the study
- Clinicians will confirm that patients' negative and positive symptoms have been stable per their clinical opinion for at least 3 months.
You likely can't join if
- Pregnancy, lactation, or an intrauterine device
- History of electroconvulsive therapy (ECT) in the past 6 months
- Use of licit or illicit substances (excluding cannabis) during the week of treatment and in the 24 hours prior to fMRI scans
- Contraindications for TMS
- Previous treatment with rTMS
- Documented history of significant intellectual disability
See the full eligibility criteria
- Confirmed diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder
- Duration of illness ≥ 6 months
- Clinically significant negative symptoms
- Must have been on a stable pharmacological treatment for at least 4 weeks before entering the study
- Clinicians will confirm that patients' negative and positive symptoms have been stable per their clinical opinion for at least 3 months.
- Participants must be able to provide informed consent
- Ability to undergo MRI scanning
- Pregnancy, lactation, or an intrauterine device
- History of electroconvulsive therapy (ECT) in the past 6 months
- Use of licit or illicit substances (excluding cannabis) during the week of treatment and in the 24 hours prior to fMRI scans
- Contraindications for TMS
- Previous treatment with rTMS
- Documented history of significant intellectual disability
- Primary diagnosis of psychotic disorder secondary to a medical condition or substance-induced psychosis.
The study team makes the final eligibility decision.
Where it is enrolling
- Verdun, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Verdun, Quebec, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.